Group 1 - The overall market trend for 2026 is expected to be optimistic, driven by a combination of fundamental, liquidity, sentiment, and policy factors [1][2] - China's GDP has surpassed 140 trillion, indicating a strong economic achievement that supports market performance [1] - Despite a recent cooling in market sentiment, the overall bullish sentiment remains high, and the market is currently undergoing a necessary adjustment phase [2] Group 2 - Historical analysis shows that previous bull markets have been characterized by short bursts of activity followed by long periods of adjustment, which negatively impacted investor experiences [3] - The current market environment is being guided towards healthier long-term development through measures such as increased margin requirements and regulatory support [4] - The AI sector remains a key focus for 2026, with strong growth expected in upstream computing power and semiconductor equipment due to expansion and rising demand [5][6] Group 3 - The innovative drug sector is projected to continue its growth trajectory in 2026, focusing on new drug platforms and expanding applications for existing treatments [6]

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report highlights the potential acceleration of the surgical robot industry following the release of the service pricing guidelines by the National Medical Insurance Administration, which clarifies the pricing structure for surgical robot services and consumables [3][18] - The report emphasizes the importance of innovation in the pharmaceutical sector, noting that the industry has completed a transition from old to new growth drivers, particularly in innovative drugs, which are expected to continue to perform well in 2026 [46][47] - The report suggests a focus on sectors such as innovative drugs, AI medical technology, and brain-computer interfaces, which are anticipated to see significant advancements in 2026 [46][48] Summary by Sections Market Performance - From January 19 to January 23, the pharmaceutical index decreased by 0.39%, with an excess return of 0.23% relative to the CSI 300 index. The market was relatively stable, with a notable increase of 1.26% on Friday, driven by themes like brain-computer interfaces and AI medical technology [5][27] - A total of 330 stocks rose while 137 fell during the week, with notable gainers including *ST Changyao (+70.37%) and Hualan Biological (+32.21%) [27][28] Surgical Robot Industry - The surgical robot market is expected to benefit from the new pricing guidelines, which will enhance the clinical application of surgical robots and promote a sustainable business model [3][18] - The domestic laparoscopic robot market is projected to grow significantly, with a compound annual growth rate (CAGR) of 29.3% from 2024 to 2030 [9][15] Investment Recommendations - The report recommends focusing on strong fundamentals and well-adjusted innovative drug stocks, including companies like Xinlitai, Zexing Pharmaceutical, and Hengrui Medicine, as well as medical technology firms like Yuyue Medical and Alibaba Health [5][49] - It also suggests monitoring companies involved in the export of CXO services and those with stable operations and low valuations that are expected to see fundamental changes in 2026 [5][46] Future Outlook - The report anticipates that the pharmaceutical industry will continue to improve marginally in 2026, driven by technological innovation and performance recovery in traditional sectors [46][47] - Key areas of focus include innovative drugs, AI medical technology, and the aging population's healthcare needs, which are expected to drive demand [46][48]

Core Viewpoint - The report from CITIC Securities indicates that while industrial production remains resilient and exports are growing rapidly, domestic demand indicators such as consumption and investment are still weak, highlighting a characteristic of "strong production versus weak demand" throughout the previous year [1] Economic Environment - The current macroeconomic environment shows similarities to the investment peak period of 2020-2021, with interbank interest rates at their lowest levels since 2020 [1] - The combination of weak macro demand and loose liquidity is expected to favor structural investment opportunities in certain sectors [1] Sector Insights - In the technology sector, AI semiconductors and new energy are identified as the core areas of current prosperity, with strong policy support for AI applications and accelerated commercialization [1] - The global capacity planning for space photovoltaics has exceeded expectations, and technological breakthroughs are opening up trillion-dollar markets [1] - The innovative drug sector is seeing value realization driven by business development transactions, clinical breakthroughs, and new drug approvals [1] Resource Sector - The non-ferrous metals industry has the highest forecasted performance improvement rate for 2025, with attention on the subsequent transmission of prosperity to the energy and machinery sectors [1] - As monetary easing continues, funds are expected to gradually shift from the financial system to the real economy, benefiting sectors such as non-ferrous metals, chemicals, machinery, and consumer goods [1] - Since December 2025, the South China Metal Index has risen by 12.5%, while the energy and industrial product indices have only increased by around 7%, suggesting better investment value in the current market [1]

围绕新"新三样"，新政策举措接连落地。 先说机器人。北京近日首设机器人专业职称，7月将启动首次评审，为的是让人才需求跟上产业热度。 上海海关为机器人上"户口"，以精准统计更好支持行业发展。从蹒跚起步到奔跑赛场、腾空起舞，机器 人加速进化。 数据来源：国家统计局等 体"。新一批在全国复制推广的25项跨境贸易便利化措施公布，支持"空中丝绸之路"发展等。政策因时 而动、因势而变，护航经济大船行稳致远。 快中有慢，方显定力。抢位更要错位，才能在空间坐标中找准接口，各展所长。 找准自身优势和全国大局的接口，在深度参与全国统一大市场建设中大展身手。追"新"，不是不顾实 际、盲目追风口，而是立足地区差异性，以一域之特色服务全局之所需。广东深圳依托珠三角制造业集 群优势，在具身智能产业上投早、投小、投硬科技。重庆人工智能湾区建设启动，发布"渝车出海"等12 个案例。这启示我们，只有正视客观差别，厚植特色优势，才能杜绝贪大求全，找准向新发展的赛 道，"既为一域争光、更为全局添彩"。 找准接口，顺势而为。4部门推进职业技能证书互通互认，促进技能人才合理顺畅流动。商务部部署健 全现代市场和流通体系，完善现代商贸流通体系。借助全国统 ...

Macro and Strategy Research - The US economy shows strong internal momentum with a 0.3% month-on-month increase in personal consumption expenditures adjusted for inflation in November 2025, marking the highest growth rate since the second half of 2025 [2] - In Europe, inflation dropped below 2% year-on-year in December 2025, indicating easing pressure, supported by labor costs and year-end consumption [3] - Domestic economic growth in China for 2025 is expected to meet targets despite a slowdown in the fourth quarter, with net exports providing structural support in early 2026 [3] Fixed Income Research - The bond market continues to show signs of recovery, with mid- to long-term bonds performing well, driven by a strong equity market and manageable bank liability pressures [5][7] - The issuance of special bonds increased significantly, with a total of 56 bonds issued, amounting to 619.1 billion yuan during the reporting period [7] - The overall bond market is characterized by a recovery trend, with the yield on 7-year government bonds declining the most [7] Industry Research - Nine departments in China have issued opinions to promote high-quality development in the pharmaceutical retail industry, indicating potential benefits for leading chain pharmacies and an expected operational turning point [10][12] - The SW pharmaceutical industry index shows a price-to-earnings ratio of 52.01, with a valuation premium of 266% relative to the CSI 300 index [11] - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring segments like small nucleic acids [12]

Group 1 - The macro environment shows easing external pressures from US-Europe relations, with a rebound in the Fed's interest rate cut trades and stable domestic macro data, alongside improvements in real estate high-frequency indicators [1] - Foreign and southbound capital continue to flow in, with public fund positions in Hong Kong stocks dropping to 23% in Q4, significantly reducing potential selling pressure [1] - The sentiment index has returned to a neutral range, with bullish expectations increasing, indicating a continued potential for a rebound in the first quarter [1] Group 2 - Focus on the AI chain (semiconductors, software) and innovative pharmaceuticals, while gradually accumulating quality consumer leaders and overweighting the upstream of the cyclical and power chains [1]

Group 1 - The QDII funds have shown impressive performance since 2025, with an average net value increase of 27.9%, particularly driven by funds heavily invested in Hong Kong innovative pharmaceuticals [2] - Notable funds such as Huatai-PB Korea Semiconductor ETF and E Fund Global Growth Select Mixed A have seen net value increases of 127.55% and 102.91% respectively, with several other funds also exceeding 80% growth [2] - The top holdings of these high-performing funds predominantly include Hong Kong innovative pharmaceutical stocks, with examples like Kelun-Botai Biotech and Innovent Biologics among the top five holdings of Huatai-PB Hong Kong Advantage Select Mixed A [2] Group 2 - The technology sector is also a key focus for many high-performing products, with E Fund Global Growth Select Mixed A holding major global tech stocks such as TSMC and Google-A among its top ten holdings [3] - Fund managers express optimism for the future of the innovative pharmaceutical and technology sectors, citing a recent phase of adjustment in the innovative drug industry as a temporary market sentiment issue rather than a fundamental change [4][5] - The innovative drug sector's valuation has become attractive, with expectations of upward potential, and the industry is anticipated to show resilience and technological attributes over the next 2 to 3 years [5] Group 3 - The pharmaceutical industry is expected to see positive changes in 2026, with contract development organizations (CXO) gaining confidence from solid data, and new technologies like artificial intelligence and brain-machine interfaces opening new application scenarios [5] - The semiconductor sector, particularly in storage, is projected to continue its cycle, with local market trends favoring leading storage manufacturers and potential IPOs supporting capacity expansion [6]

Investment Rating - The report suggests a positive outlook for the innovative drug sector, indicating it will continue to be a core investment direction in 2026 due to the maturation of the industry chain and normalization of medical insurance negotiations [4]. Core Insights - The public fund's pharmaceutical holdings decreased to 8.11% in Q4 2025, down by 1.66 percentage points (pp) from the previous quarter. Excluding actively managed pharmaceutical funds, the holdings dropped to 3.90%, a decrease of 1.36pp [11][12]. - The innovative drug ETF reached a scale of 100.62 billion yuan in Q4, accounting for 13.11% of the pharmaceutical fund, which is a slight decrease of 1.35pp [13][15]. - The CXO sector saw a decline in holdings due to geopolitical disturbances, while the medical device sector benefited from innovations like brain-computer interfaces and surgical robots, leading to an increase in holdings [14][17]. - The report highlights the acquisition of PART by GSK for $2.2 billion to strengthen its position in the IgE antibody market, with the core product Ozureprubart showing significant market potential [2][31]. - The oral weight loss drug Wegovy has shown strong early commercial progress, with retail prescriptions reaching approximately 3,071 in the first four days post-launch, nearly three times that of its competitor Zepbound [2][31]. Summary by Sections Pharmaceutical Sector - The report indicates a significant decrease in public fund holdings in the pharmaceutical sector, with a noted resilience in the innovative drug segment [11][14]. - The report emphasizes the importance of focusing on leading companies with core pipeline competitiveness and global layout capabilities for investment [4]. Medical Devices - The introduction of new pricing guidelines for auxiliary medical services is expected to accelerate the adoption of innovative products in the medical device sector [3][17]. - The report suggests monitoring domestic leading companies in this sector for increasing product penetration [3]. Drugstores - The report discusses the potential for leading drugstore companies to increase market share, supported by recent government policies promoting high-quality development in the retail pharmaceutical industry [3][17]. - Specific companies like Yifeng Pharmacy and Dazhenglin are highlighted as having low valuations and significant cost reduction achievements [3]. CXO and Pharmaceutical Supply Chain - Several CXO companies have released optimistic earnings forecasts for 2025, indicating a clear upward trend in industry prosperity [2][31]. - The report recommends active investment in this sector due to the positive signals regarding industry growth [2][31].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical industry but emphasizes a positive outlook on various segments within the industry, particularly innovative drugs and medical devices [9][10]. Core Insights - The pharmaceutical industry is transitioning from a quantity-driven logic to a quality-driven logic, focusing on differentiated products and internationalization by 2025 [9]. - There is a notable shift in funding from active to passive medical funds, indicating a low allocation status in the pharmaceutical sector, which is expected to change as passive funds become a significant part of the investment landscape [16][17]. - The report outlines a structured approach to ETF investment in the pharmaceutical sector, emphasizing a dynamic combination of broad-based and targeted strategies to balance returns and risks [27]. Summary by Sections Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 sectors [6]. - The top-performing stocks included *ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, while the worst performers were Kaiyin Technology and Aidi Pharmaceutical [6]. Innovative Drugs - The report highlights a positive outlook for domestic innovative drugs, suggesting a focus on companies that can deliver profits, such as BeiGene, Innovent Biologics, and others [9]. Medical Devices - The medical device sector is expected to see a recovery in bidding volumes for imaging equipment by 2025, with a focus on companies like Mindray and United Imaging [9]. - The home medical device market is also anticipated to grow due to supportive policies and accelerated international expansion [9]. Innovation Chain (CXO + Life Science Services) - The report indicates a potential recovery in overseas investment and financing, with domestic financing expected to stabilize, marking the beginning of a new wave of innovation [9]. Pharmaceutical Industry - The report suggests that the specialty API sector may see cost improvements, leading to a new growth cycle, with companies like Tonghua Dongbao and Huahai Pharmaceutical highlighted for their potential [9]. Traditional Chinese Medicine - The report discusses the expected growth in the basic drug market and the impact of state-owned enterprise reforms on companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical [11]. Pharmacy Sector - The report expresses optimism about the pharmacy sector due to the acceleration of prescription outflow and the optimization of competitive dynamics, recommending companies like YaoXing and YiFeng Pharmacy [11]. Medical Services - The report notes that anti-corruption measures and centralized procurement are improving the market environment for private medical services, with recommendations for companies like Huashan Medical and Aier Eye Hospital [11]. Blood Products - The report anticipates a favorable long-term growth path for the blood products industry, with companies like TianTan Biological and Boya Biological expected to benefit from increased demand and supply elasticity [11].

Core Viewpoint - The article discusses the investment framework for the pharmaceutical industry ETF in 2026, emphasizing a dual-driven approach of demand and innovation to navigate the market recovery and differentiation after a prolonged bear market since 2021 [29]. Market Review - The CITIC Pharmaceutical Index decreased by 0.38%, outperforming the CSI 300 Index by 0.24 percentage points, ranking 25th among 30 primary industries [9]. - The top ten stocks by increase this week included ST Changyao, Hualan Biological Engineering, and Kangzhong Medical, with gains ranging from 6% to 70.38% [9]. - The bottom ten stocks by decrease included Kain Technology and Aidi Pharmaceutical, with declines of up to 45% [9]. Industry and Stock Events - The article highlights a shift in funding from active to passive management in the pharmaceutical sector, with passive funds becoming a significant part of the long-term funding structure [18]. - The article notes that the innovation drug sector is expected to see a transition from quantity to quality, focusing on differentiated products and internationalization by 2025 [12]. - The medical device sector is experiencing a recovery in bidding volumes, particularly in imaging equipment, and is benefiting from policies promoting home medical devices and accelerated overseas expansion [12]. - The article discusses the favorable conditions for the blood products industry, with relaxed approval for plasma stations and a clear growth path for the industry during the 14th Five-Year Plan period [13]. Investment Strategy - The article proposes a dynamic ETF configuration framework for the pharmaceutical sector, categorized into three layers: a core base of broad-based ETFs, a dual-driven layer focusing on innovative drugs and medical devices, and a defensive layer using traditional Chinese medicine and overseas biotech [22]. - The article emphasizes the importance of a systematic approach to ETF selection, considering liquidity, tracking quality, and cost [24]. - It suggests that the pharmaceutical sector is entering a new growth cycle driven by rigid demand and continuous innovation, necessitating a more structured and rhythmic ETF combination strategy [22].